References

1. Cancer stat facts: pancreatic cancer. National Cancer Institute. Accessed July 17, 2024. https://seer.cancer.gov/statfacts/html/pancreas.html

2. Adamska A, Domenichini A, Falasca M. Pancreatic ductal adenocarcinoma: current and evolving therapies. Int J Mol Sci. 2017;18(7):1338. doi:10.3390/ijms18071338

3. NCCN. Clinical Practice Guidelines in Oncology. Pancreatic adenocarcinoma, version 2.2024. Updated April 30, 2024. Accessed July 19, 2024. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf

4. Knox JJ, Jaffee EM, O’Kane GM, et al. Early results of the PASS-01 trial: pancreatic adenocarcinoma signature stratification for treatment-01. J Clin Oncol. 2024;42(suppl 17):LBA4004. doi:10.1200/JCO.2024.42.17_suppl.LBA4004

5. Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272-1281. doi:10.1016/S0140-6736(23)01366-1

6. Van Laethem JL, Borbath I, Prenen H, et al. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study. Lancet Oncol. 2024;25(7):853-864. doi:10.1016/S1470-2045(24)00263-8

7. Laethem J-LV, Borbath I, Geboes KP, et al. OPTIMIZE-1 primary analysis: safety, efficacy and biomarker results of a phase 1b/2 study combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC). J Clin Oncol. 2024;42(suppl 16):4133. doi:10.1200/JCO.2024.42.16_suppl.4133

8. Wainberg ZA, Manji GA, Bahary N, et al. ARC-8: phase 1/1b randomized study of quemliclustat +  gemcitabine/nab-paclitaxel ± zimberelimab in patients with treatment-naive metastatic pancreatic adenocarcinoma. J Clin Oncol. 2024;42(suppl 3):665. doi:10.1200/JCO.2024.42.3_suppl.665

9. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317-327. doi:10.1056/NEJMoa1903387

10. Park W, O’Connor C, Chou JF, et al. Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy. J Clin Oncol. 2023;41(suppl 16):4140. doi:10.1200/JCO.2023.41.16_suppl.4140

11. Pant S, Yaeger R, Spira AI, et al. KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRASG12C mutation. J Clin Oncol. 2023;41(suppl 36):425082. doi:10.1200/JCO.2023.41.36_suppl.425082

12. Murciano-Goroff YR, Heist RS, Kuboki Y, et al. A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors. Presented at: 2023 American Association for Cancer Research Annual Meeting; April 14-19, 2023; Orlando, FL.

13. Sacher A, LoRusso P, Patel MR, et al; GO42144 Investigator and Study Group. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N Engl J Med. 2023;389(8):710-721. doi:10.1056/NEJMoa2303810

14. Li J, Shen L, Gu Y, et al. Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors. J Clin Oncol. 2024;42(suppl 3):604. doi:10.1200/JCO.2024.42.3_suppl.604